Description

MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values ＜ 1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(−) susceptibility[1].–Applications–Formula-C9H12BN7O5S2-Citation–References-[1]Rachel A. Powers, et al. Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum. J Med Chem. 2023 Jul 13; 66(13): 8510–8525.-CASNumber-2832966-95-5-MolecularWeight-373.18-Compound Purity–SMILES-NC1=NN=C(SCC(N[C@H](B(O)O)CN2C=C(C(O)=O)N=N2)=O)S1-Research_Area-Others-Solubility-10 mM in DMSO-Target-Others-Isoform–Pathway-Others-MCE Product type-ADC Related